APOE and fatty liver disease: In agreement with the notion that saringosterol has a selective action for LXRβ, unlike pan-LXR agonist T0901317 [26], we found that saringosterol treatment did not exacerbate hepatic steatosis in atherosclerotic ApoE−/− mice.